Resonance Health Banks $733K R&D Refund While Turning a Profit in FY25
Resonance Health is an innovative MedTech company specializing in advanced medical imaging analysis solutions. Headquartered in Australia, the company focuses on developing cutting-edge, non-invasive technologies that help healthcare professionals make more precise diagnostic and treatment decisions. Their core expertise lies in creating sophisticated MRI-based analysis tools for assessing liver and cardiac conditions with exceptional accuracy and efficiency.
The company’s product portfolio includes several key technologies such as FerriScan®, FerriSmart®, LiverSmart®, HepaFatSmart®, and Cardiac T2*, which are designed to provide detailed insights into liver iron concentration, liver fat, and heart iron levels. These solutions utilize advanced AI-powered engines and are performed through quick, painless MRI scans that generate comprehensive reports within 2 business days. By leveraging sophisticated algorithms and expert analysis, Resonance Health enables clinicians to obtain precise measurements and actionable medical information.
Driven by a mission to empower healthcare providers and improve patient outcomes, Resonance Health combines medical expertise with technological innovation. Their technologies are particularly valuable for managing complex conditions that require detailed imaging analysis, such as hemochromatosis, liver diseases, and cardiac iron overload. The company’s commitment to personalized care, non-invasive diagnostic methods, and rapid result delivery positions them as a leader in medical imaging technology, helping physicians make more informed decisions and deliver tailored patient care.